A Modified Tyrosinase-Related Protein 2 Epitope Generates High-Affinity Tumor-Specific T Cells but Does Not Mediate Therapeutic Efficacy in an Intradermal Tumor Model
Authors:
- 1 July 2006
- journal article
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 177 (1) , 155-161
Abstract
The generation of tumor-specific T cells is hampered by the presentation of poorly immunogenic tumor-specific epitopes by the tumor. Here, we demonstrate that, although CD8+ T cells specific for the self/tumor Ag tyrosinase-related protein 2 (TRP2) are readily detected in tumor-bearing hosts, vaccination of either tumor-bearing or naive mice with an epitope derived from TRP2 fails to generate significant numbers of tetramer-staining TRP2-specific T cells or antitumor immunity. We identified an altered peptide epitope, called deltaV, which elicits T cell responses that are cross-reactive to the wild-type TRP2 epitope. Immunization with deltaV generates T cells with increased affinity for TRP2 compared with immunization with the wild-type TRP2 epitope, although TRP2 immunization often generates a greater number of TRP2-specific T cells based on intracellular IFN-γ analysis. Despite generating higher affinity responses, deltaV immunization alone fails to provide any greater therapeutic efficacy against tumor growth than TRP2 immunization. This lack of tumor protection is most likely a result of both the deletion of high affinity and functional tolerance induction of lower affinity TRP2-specific T cells. Our data contribute to a growing literature demonstrating the ability of variant peptide epitopes to generate higher affinity T cell responses against tumor-specific Ags. However, consistent with most clinical data, simple generation of higher affinity T cells is insufficient to mediate tumor immunity.Keywords
This publication has 35 references indexed in Scilit:
- Mimotopes for Alloreactive and Conventional T Cells in a Peptide–MHC Display LibraryPLOS Biology, 2004
- Combined TLR and CD40 Triggering Induces Potent CD8+ T Cell Expansion with Variable Dependence on Type I IFNJournal of Experimental Medicine, 2004
- T cells down-modulate peptide-MHC complexes on APCs in vivoNature Immunology, 2001
- Elucidating the Autoimmune and Antitumor Effector Mechanisms of a Treatment Based on Cytotoxic T Lymphocyte Antigen-4 Blockade in Combination with a B16 Melanoma VaccineJournal of Experimental Medicine, 2001
- Identification of Tyrosinase-related Protein 2 as a Tumor Rejection Antigen for the B16 MelanomaJournal of Experimental Medicine, 1997
- Identification of TRP-2 as a Human Tumor Antigen Recognized by Cytotoxic T LymphocytesJournal of Experimental Medicine, 1996
- Tyrosinase and related proteins in mammalian pigmentationFEBS Letters, 1996
- Induction of protective cytotoxic T cells with viral proteinsEuropean Journal of Immunology, 1994
- Changes at peptide residues buried in the major histocompatibility complex (MHC) class I binding cleft influence T cell recognition: a possible role for indirect conformational alterations in the MHC class I or bound peptide in determining T cell recognition.Journal of Experimental Medicine, 1993
- Empty MHC class I molecules come out in the coldNature, 1990